Elizabeth E Richards

US Patent:

48701637, Sep 26, 1989

Filed:

Aug 29, 1985

Appl. No.:

6/770808

Inventors:

Berish Y. Rubin - Brooklyn NY
Sylvia L. Anderson - New York NY
Susan A. Sullivan - Brooklyn NY
Lloyd J. Old - New York NY
Barbara D. Williamson - Old Greenwich CT
Elizabeth C. Richards - Tarrytown NY

Assignee:

New York Blood Center, Inc. - New York NY
Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

C07K 312
C07K 318
C07K 320

US Classification:

530413

Abstract:

Human TNF(LuKII) having a specific activity of at least 1. 5. times. 10. sup. 5 units per milligram of total protein is produced by contacting a TNF-containing protein composition, which has been harvested from human cell lines of hematopoietic origin or recombinant origin, in separate adsorption stages with glass beads, lentil lectin bound to Sepharose, and procion red agarose, thereby selectively to adsorb TNF in each stage, while leaving some impurities unadsorbed, each contact stage being followed by contact of the adsorbent with an eluant thereby to obtain a solution of more highly purified TNF after each stage. The purified human TNF(LuKII) is used to produce monoclonal antibodies against TNF(LuKII) and such antibodies can be used to assay samples for the presence of TNF(LuKII).

US Patent:

61906409, Feb 20, 2001

Filed:

Nov 19, 1996

Appl. No.:

8/752693

Inventors:

Sydney Welt - New York NY
Gerd Ritter - New York NY
Leonard Cohen - New York NY
Clarence Williams - New York NY
Elizabeth Carswell Richards - New York NY
Mary John - New York NY
Lloyd J. Old - New York NY

Assignee:

Ludwig Institute for Cancer Research - London
Sloan-Kettering Institute for Cancer Research - NY

International Classification:

A61K 5100
A61K 4900
A61K 3514

US Classification:

424 149

Abstract:

The invention involves the therapeutic use of humanized antibodies, fragments, etc. , which bind to the antigen A33. These antibody molecules are useful in the treatment of various neoplasias, including colon cancer. Various modes of administration, and doses are described.

US Patent:

58515267, Dec 22, 1998

Filed:

May 25, 1995

Appl. No.:

8/449911

Inventors:

Sydney Welt - New York NY
Gerd Ritter - New York NY
Leonard Cohen - New York NY
Clarence Williams - New York NY
Elizabeth Carswell Richards - New York NY
Mary John - New York NY
Lloyd J. Old - New York NY

Assignee:

Ludwig Institute for Cancer Research - New York NY

International Classification:

A61K 39395
A61K 3900

US Classification:

4241561

Abstract:

This invention relates to methods of reducing the effects of colon cancer tumors. Various agents are conjugated to monoclonal antibodies which are specific for colon cancer cells. The conjugates are administered to patients having colon cancer such that the effects of the cancer are reduced.

US Patent:

47709952, Sep 13, 1988

Filed:

Aug 29, 1985

Appl. No.:

6/770804

Inventors:

Berish Y. Rubin - Brooklyn NY
Sylvia L. Anderson - New York NY
Susan A. Sullivan - Brooklyn NY
Lloyd J. Old - New York NY
Barbara D. Williamson - Old Greenwich CT
Elizabeth C. Richards - Tarrytown NY

Assignee:

New York Blood Center, Inc - New York NY
Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

G01N 5300
G01N 33566
G01N 33532
G01N 33534

US Classification:

435 7

Abstract:

A process for predicting the sensitivity of cells, e. g. , tumor cells, to the effects of tumor necrosis factor or lymphotoxin involving ascertaining the binding of the tumor necrosis factor or lymphotoxin to the cells, i. e. , measuring the number of receptors on the cells.

US Patent:

50233203, Jun 11, 1991

Filed:

Jul 14, 1988

Appl. No.:

7/219093

Inventors:

Katsuyuki Haranaka - Kokubunji, JP
Lloyd J. Old - New York NY
Elizabeth C. Richards - Westport CT
Barbara Williamson - Old Greenwich CT

Assignee:

Sloan-Kettering Institute For Cancer Research - New York NY

International Classification:

C07K 1504
C07K 328

US Classification:

530350

Abstract:

A process is provided for the purification of a proteinaceous physiologically active substance having antitumor activity, which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotroxin from a Gram-negative bacterium into the rabbit. The process comprises contacting a crude solution of said proteinaceous physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, eluting the adsorbed physiologically active substance, and subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight in the range of 30,000 to 70,000. The purified preparation of said physiologically active substance thus obtained may be used as an antitumore agent for the treatment of malignant tumors. Said physiologically active substance is isolated by subjecting the purified preparation successively to affinity chromatography on immobilized Cibarcron Blue F3G-A, gel filtration, affinity chromatography on immobilized concanavalin A, preparative electrophoresis on polyacrylamide gel and gel filtration.